soul trial oral semaglutide cardiovascular outcomes trial results Trial: Reduces Events in T2DM Patients | Stanley M. Samusodza, MD, MScSM posted on the topic Semaglutide in Cardiometabolic Diseases: SELECTing

For us as clinicians, the 2035 projections map directly onto the chronic disease burden we'll be managingmore diabetes, more cardiovascular disease, more musculoskeletal disease, more Alzheimer's, and higher costs across the board

This weight loss injection has shown great results: over 68 weeks, patients taking the drug lost 15-20% of their body weight, compared to 2.4% in patients taking a placebo

There is no clinical data supporting split-dose semaglutide administration, and the FDA-approved protocols call for a single weekly injection

Mistake 4: No temperature verification Without a thermometer strip, you are guessing